139 related articles for article (PubMed ID: 30651938)
1. Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Munari E; Zamboni G; Marconi M; Sommaggio M; Brunelli M; Martignoni G; Netto GJ; Moretta F; Mingari MC; Salgarello M; Terzi A; Picece V; Pomari C; Lunardi G; Cavazza A; Rossi G; Moretta L; Bogina G
Oncotarget; 2018 Dec; 9(97):37077. PubMed ID: 30651938
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Munari E; Zamboni G; Marconi M; Sommaggio M; Brunelli M; Martignoni G; Netto GJ; Moretta F; Mingari MC; Salgarello M; Terzi A; Picece V; Pomari C; Lunardi G; Cavazza A; Rossi G; Moretta L; Bogina G
Oncotarget; 2017 Oct; 8(52):90123-90131. PubMed ID: 29163815
[TBL] [Abstract][Full Text] [Related]
3. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
Kitazono S; Fujiwara Y; Tsuta K; Utsumi H; Kanda S; Horinouchi H; Nokihara H; Yamamoto N; Sasada S; Watanabe S; Asamura H; Tamura T; Ohe Y
Clin Lung Cancer; 2015 Sep; 16(5):385-90. PubMed ID: 25937270
[TBL] [Abstract][Full Text] [Related]
4. Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer.
Gradecki SE; Grange JS; Stelow EB
Am J Surg Pathol; 2018 Aug; 42(8):1090-1094. PubMed ID: 29794870
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
Nakamura S; Hayashi K; Imaoka Y; Kitamura Y; Akazawa Y; Tabata K; Groen R; Tsuchiya T; Yamasaki N; Nagayasu T; Fukuoka J
PLoS One; 2017; 12(10):e0186192. PubMed ID: 29049375
[TBL] [Abstract][Full Text] [Related]
6. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263.
Munari E; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Brunelli M; Martignoni G; Netto GJ; Hoque MO; Moretta F; Mingari MC; Pegoraro MC; Mariotti FR; Vacca P; Moretta L; Bogina G
Oncotarget; 2018 Jul; 9(54):30465-30471. PubMed ID: 30101000
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
9. Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
Xu N; Fang W; Mu L; Tang Y; Gao L; Ren S; Cao D; Zhou L; Zhang A; Liu D; Zhou C; Wong KK; Yu L; Zhang L; Chen L
Oncotarget; 2018 Oct; 9(81):35284. PubMed ID: 30443296
[TBL] [Abstract][Full Text] [Related]
10. Correction: Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.
Kageyama SI; Nihei K; Karasawa K; Sawada T; Koizumi F; Yamaguchi S; Kato S; Hojo H; Motegi A; Tsuchihara K; Akimoto T
Oncotarget; 2018 May; 9(34):23844. PubMed ID: 29809194
[TBL] [Abstract][Full Text] [Related]
11. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Xing YF; Pan X; Qian B; Shi MH
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
[No Abstract] [Full Text] [Related]
12. Correction: Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer.
Terlizzi M; Colarusso C; De Rosa I; De Rosa N; Somma P; Curcio C; Sanduzzi A; Micheli P; Molino A; Saccomanno A; Salvi R; Aquino RP; Pinto A; Sorrentino R
Oncotarget; 2018 Jun; 9(50):29537. PubMed ID: 30034638
[TBL] [Abstract][Full Text] [Related]
13. EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Sakakibara R; Inamura K; Tambo Y; Ninomiya H; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Matsuura Y; Nakao M; Mun M; Okumura S; Inase N; Nishio M; Motoi N; Ishikawa Y
Clin Lung Cancer; 2017 Sep; 18(5):527-534.e1. PubMed ID: 28111119
[TBL] [Abstract][Full Text] [Related]
14. Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D; Rounis K; Tsigkas AP; Georgiou A; Galanakis N; Tsakonas G; Ekman S; Papadaki C; Monastirioti A; Kontogianni M; Gioulbasanis I; Mavroudis I; Agelaki S
PLoS One; 2023; 18(11):e0294384. PubMed ID: 37943779
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.
Vigliar E; Malapelle U; Iaccarino A; Acanfora G; Pisapia P; Clery E; De Luca C; Bellevicine C; Troncone G
J Clin Pathol; 2019 Jun; 72(6):412-417. PubMed ID: 30846480
[TBL] [Abstract][Full Text] [Related]
16. Correction:
Madic J; Jovelet C; Lopez J; André B; Fatien J; Miran I; Honoré A; Mezquita L; Besse B; Lacroix L; Droniou M
Oncotarget; 2019 Feb; 10(13):1345. PubMed ID: 30863495
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Farkašová A; Tancoš V; Kviatkovská Z; Huťka Z; Mičák J; Scheerová K; Szépe P; Plank L
Cesk Patol; 2018; 54(3):137-142. PubMed ID: 30445818
[TBL] [Abstract][Full Text] [Related]
18. Correction: Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed.
Zhang N; Kong L; Shi F; Jing W; Wang H; Yang M; Yu J; Zhu H
Oncotarget; 2017 Dec; 8(66):110732. PubMed ID: 29300397
[TBL] [Abstract][Full Text] [Related]
19. Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
Han JJ; Kim DW; Koh J; Keam B; Kim TM; Jeon YK; Lee SH; Chung DH; Heo DS
Clin Lung Cancer; 2016 Jul; 17(4):263-270.e2. PubMed ID: 26707383
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
